RN486, a Bruton's Tyrosine Kinase inhibitor, antagonizes multidrug resistance in ABCG2-overexpressing cancer cells.

Xing-Duo DongQisi LuYi-Dong LiChao-Yun CaiQiu-Xu TengZi-Ning LeiZeng-Hui WeiFan YinLeli Zeng Zhe-Sheng Chen

Published in: Journal of translational internal medicine (2024)

Our studies propose that RN486 can antagonize ABCG2-mediated MDR in cancer cells via down-regulating the expression level of ABCG2 protein, reducing ATPase activity of ABCG2 transporter, and inhibiting the transporting function. RN486 could be potentially used in conjunction with chemotherapy to alleviate MDR mediated by ABCG2 in cancer.

Keyphrases

cancer stem cells
multidrug resistant
poor prognosis
signaling pathway
papillary thyroid
binding protein
squamous cell carcinoma
radiation therapy
rectal cancer